|
Prescription Drug Search
Strengths available for Fanapt:
Browse Alphabetically:
A
·
B
·
C
·
D
·
E
·
F
·
G
·
H
·
I
·
J
·
K
·
L
·
M
·
N
O
·
P
·
Q
·
R
·
S
·
T
·
U
·
V
·
W
·
X
·
Y
·
Z
·
#
Information about MyGlobalPharmacy.com
List of countries where we can ship Fanapt:
- Azerbaijan
- Bahamas
- Bangladesh
- Barbados
- Belgium
- Belize
- Bolivia
- Bosnia and Herzegovina
- Bulgaria
- China
- Costa Rica
- Cuba
- Czech Republic
- Denmark
- Dominican Republic
- Ecuador
- Egypt
- France
- Georgia
- Gibraltar
- India
- Ireland
- Italy
- Lebanon
- Lithuania
- Malta
- Moldova, Republic of
- Netherlands
- Netherlands Antilles
- Philippines
- Russian Federation
- Serbia
- Singapore
- Slovakia
- South Africa
- Tunisia
- United Kingdom, UK
- United States, US
- Uruguay
- Vanuatu
Latest news releases on Fanapt:
Vanda takes 1Q loss on sleep disorder drug costs - Yahoo Finance
Its royalty revenue rose to $1.5 million from $895,000. The company gets royalties on sales of the schizophrenia drug Fanapt, which is marketed by Swiss drugmaker Novartis AG. Vanda said Fanapt prescriptions grew 39 percent from a year ago.
Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting - Yahoo Finance
sales and marketing and distribution support Fanapt® receives; Vanda's ability to successfully commercialize Fanapt® outside of the U.S. and Canada; delays in the completion of Vanda's clinical trials; a failure of Vanda's products ...
Vanda Pharmaceuticals Reports First Quarter 2012 Results - Daily Markets
First quarter 2012 revenues included $1.5 million in Fanapt® royalties received from Novartis as compared to royalties of $0.9 million for the first quarter of 2011. Total operating expenses for the first quarter of 2012 were $16.5 ...
Vanda Pharmaceuticals reports $8M loss - The Business Journal
The company's revenue climbed to $8.14 million, from $7.5 million in the same quarter a year ago on higher royalty payments from Novartis for its schizophrenia drug, Fanapt. Vanda had a first quarter net loss of $7.96 million, or 28 cents per ...
Vanda Pharmaceuticals Inc. Earnings Conference Call (Q1 2012) - Yahoo! Finance
Its lead product includes Fanapt for the acute treatment of schizophrenia in adults. The company is developing Tasimelteon, which is in the orphan designation status for the treatment of non-24 hour sleep/wake disorder in blind individuals without light perception.
Titan Pharmaceuticals Announces First Quarter 2012 Financial Results Titan Management Team to Host Conference Call May 16 at 1 p.m. ET / 10 a.m. PT - PR Inside
First quarter 2012 revenues consisted primarily of $1.2 million in royalties on net sales of Fanapt®, which will be paid by Titan to Deerfield Management Company L.P. in accordance with the terms of the agreements entered into during 2011. First quarter ...
